


# Journal Pre-proof



Pharmaceuticals in the Blubber of Live Free-Swimming Common Bottlenose Dolphins  
(*Tursiops truncatus*)

Anya Isabelle Ocampos, Makayla A. Guinn, Justin Elliott, Christiana Wittmaack,  
Carrie Sinclair, Hussain Abdulla, Dara N. Orbach

PII: S2589-0042(24)02734-2

DOI: <https://doi.org/10.1016/j.isci.2024.111507>

Reference: ISCI 111507

To appear in: *ISCIENCE*

Received Date: 4 August 2024


Revised Date: 16 October 2024

Accepted Date: 27 November 2024

Please cite this article as: Ocampos, A.I., Guinn, M.A., Elliott, J., Wittmaack, C., Sinclair, C., Abdulla, H., Orbach, D.N., Pharmaceuticals in the Blubber of Live Free-Swimming Common Bottlenose Dolphins (*Tursiops truncatus*), *ISCIENCE* (2024), doi: <https://doi.org/10.1016/j.isci.2024.111507>.

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2024 Published by Elsevier Inc.



Journal Pre-proof

1 Pharmaceuticals in the Blubber of Live Free-Swimming Common Bottlenose Dolphins (*Tursiops*  
2 *truncatus*)

3 Authors: Anya Isabelle Ocampos<sup>1</sup>, Makayla A. Guinn<sup>1</sup>, Justin Elliott<sup>1</sup>, Christiana Wittmaack<sup>2</sup>,  
4 Carrie Sinclair<sup>3</sup>, Hussain Abdulla<sup>1</sup>, and Dara N. Orbach<sup>1,4\*</sup>

5  
6 Affiliations:

7 <sup>1</sup>College of Science, Texas A&M University-Corpus Christi, Corpus Christi, 78412, TX, USA.

8 <sup>2</sup>Precision Toxicological Consultancy, Monroe, 28110, NC, USA.

9 <sup>3</sup>National Oceanic and Atmospheric Administration, Southeast Fisheries Science Center,  
10 Mississippi Laboratories, Pascagoula, 39567, MS, USA.

11  
12 \*Corresponding author. Email: [dnorbach@gmail.com](mailto:dnorbach@gmail.com)

## 14 **Summary**

15 Pharmaceuticals prevent and treat diseases, yet inappropriate intake can result in harmful effects  
16 including mortality. Contaminants have become recurrent public and wildlife health concerns.  
17 Bioaccumulation of contaminants can occur throughout trophic levels of the food web. Dolphins  
18 are apex predators often used as sentinel species to assess the health of marine ecosystems  
19 because their lipid-rich blubber stores contaminants. We used blubber samples collected from  
20 live free-swimming and post-mortem common bottlenose dolphins (*Tursiops truncatus*) in the  
21 Gulf of Mexico to explore the presence of pharmaceutical contaminants in the marine ecosystem.  
22 Targeted analysis of blubber using ultra-performance liquid chromatography coupled with  
23 Orbitrap Fusion Tribrid mass spectrometry confirmed the presence of fentanyl, carisoprodol, or

<sup>4</sup> Lead Contact

24 meprobamate in 30 of the 89 dolphins assessed. We provide the first detection of human  
25 pharmaceuticals stored in live free-swimming marine mammals, with important implications for  
26 understanding ecosystem health.

27

## 28 **Introduction**

29 Pharmaceutical drugs are therapeutic substances used in human and veterinary medicine to  
30 diagnose, treat, cure, or prevent disease(s). Improper use of pharmaceuticals can cause harmful  
31 effects including antibiotic resistance, addiction, overdose, and mortality<sup>1,2</sup>. For example,  
32 improper use of veterinary pharmaceuticals in terrestrial mammals may result in hypersensitivity  
33 reactions, gastric effects, hepatotoxicity, anaphylaxis, and mortality<sup>3</sup>. Pharmaceuticals and active  
34 pharmaceutical ingredients (APIs) have become emerging micropollutants and are a growing  
35 global concern<sup>4,5</sup>. The presence of pharmaceutical residues and APIs has been reported in  
36 freshwater ecosystems, rivers, and oceans worldwide<sup>6,7</sup>. The transfer of human pharmaceuticals  
37 into aquatic environments often occur through insufficient treatment of wastewater effluent and  
38 untreated discharge from pharmaceutical manufacturing facilities<sup>7,8,9,10</sup>. Conventional treatment  
39 methods implemented by wastewater treatment plants have pharmaceutical removal efficiencies  
40 ranging from 23-54%<sup>11</sup>. Residual veterinary pharmaceuticals in animal manure may enter aquatic  
41 systems through runoff<sup>12</sup>. Dietary medicinal doses are commonly directly lost from aquaculture  
42 and shrimp farming to aquatic ecosystems<sup>8,13</sup>.

43         Pharmaceuticals are biologically active compounds that interact with specific  
44 physiological pathways. Pharmaceuticals including hypocholesterolaemic drugs, beta blockers,  
45 cardiovascular drugs, non-steroidal anti-inflammatory drugs, steroid hormone drugs, psychiatric

<sup>4</sup> Lead Contact

46 drugs, and antibiotics can bioaccumulate in marine invertebrates (e.g., crustaceans, mussels,  
47 shrimp) and fish<sup>14, 15, 16</sup>; most studies on trophic transfer in aquatic environments were conducted  
48 in freshwater rivers or lakes lacking higher aquatic apex predators<sup>7, 15, 17, 18</sup>. The exposure of fish  
49 to anxiolytic (oxazepam) and analgesic (carbamazepine, paracetamol)/ angiotensin II receptor  
50 blocker (irbesartan)/ nonsteroidal anti-inflammatory (naproxen, diclofenac) drugs can result in  
51 behavioral alterations and endocrine disruptions, respectively<sup>19, 20, 21</sup>. Humans can indirectly  
52 consume many classes of pharmaceuticals from drinking water and food products<sup>22</sup> (e.g.,  
53 contaminated fish and seafood), which may be a public health concern<sup>23</sup>. Drug residue intake  
54 from consuming edible animal tissues exposed to antimicrobial drugs (e.g., sulfamides,  
55 lincosamides) may have short-term (e.g., allergic reactions) and long-term (e.g., mutagenic,  
56 carcinogenic, and teratogenic) effects on human health<sup>24</sup>. Reports of human pharmaceuticals  
57 stored in free-swimming apex marine predators are limited to a few studies<sup>25, 26, 27</sup>. One  
58 population of bull sharks (*Carcharhinus leucas*) inhabiting a wastewater-impacted river had  
59 detectable human contraceptive and anti-depressant metabolites in plasma<sup>26</sup>. Recently, muscle  
60 relaxants or migraine medications were detected in low concentrations (<1 ng/g) in the livers and  
61 antihistamines in the blubber of seven post-mortem dolphins, highlighting that detection is  
62 dependent on the tissue matrix and properties of the medications (e.g., lipophilic)<sup>27</sup>.  
63 Antidepressants were reported in the feces of captive killer whales (*Orcinus orca*), although it is  
64 not clear if the animals were treated with the pharmaceuticals and there was no evidence of drug  
65 storage<sup>28</sup>.

66 Common bottlenose dolphins (*Tursiops truncatus*; hereafter 'dolphins') are susceptible to  
67 bioaccumulation of lipophilic compounds from pollutants and are effective bioindicators of  
68 ecosystem health in contaminant research; common bottlenose dolphins have lipid-rich blubber

69 that can store contaminants and be sampled relatively minimally invasively, high trophic level  
70 positions in food webs, long lifespans, and relatively fast metabolisms<sup>29, 30, 31</sup>. It remains unclear  
71 what are the chronic effects of pharmaceuticals in dolphins. We used liquid chromatography  
72 coupled with Orbitrap Fusion Tribrid mass spectrometry (LC-OT-MS) to evaluate the presence  
73 and concentrations of human pharmaceuticals stored in the blubber of free-swimming, *in vivo*,  
74 and post-mortem dolphins off three locations in the Gulf of Mexico (GoM). Level 1 confidence  
75 was achieved. Other matrices known to accumulate pharmaceuticals in vertebrates were not  
76 sampled as that would require the subjects to be post-mortem (e.g., liver, brain, kidney tissues) or  
77 entail highly invasive and logistically constraining collection techniques (e.g., plasma, urine) that  
78 would substantially reduce the sample size.

79 Fentanyl (an opioid analgesic for severe pain that is 100x more potent than morphine<sup>32</sup>),  
80 carisoprodol (a muscle relaxant for painful musculoskeletal injuries), and meprobamate (a  
81 sedative and anxiolytic drug for treating anxiety disorders) were selected based on an untargeted  
82 analysis (Methods S1). Fentanyl targets the brain and binds to opioid receptors. Upon ingestion,  
83 fentanyl passes through the stomach and intestine where it can subsequently be defecated or  
84 transferred to the liver and metabolized by CYP3A4 (CYP3A29 is the homologue in cetacean  
85 skin<sup>33</sup>) and excreted in urine. Inhalation and dermal contact with fentanyl reach the brain, fat,  
86 kidney, and liver by blood transport. The half-life of fentanyl is 3-7 hr<sup>34</sup>. Carisoprodol and  
87 meprobamate are metabolized in the liver by the cytochrome P450 system<sup>35, 36</sup>. The half-life of  
88 carisoprodol is 2 hr while its metabolite meprobamate has a half-life of 10 hr<sup>37</sup>. The metabolism  
89 of fentanyl, carisoprodol, and meprobamate have not been assessed in cetaceans to our  
90 knowledge.

91

<sup>4</sup> Lead Contact

## 92 **Results**

### 93 *LOD and LOQ*

94 A total of 89 blubber samples were analyzed from different dolphins (83 biopsy collected, 6 post-  
95 mortem) inhabiting Redfish Bay, TX (RB, n = 46; Fig 1a), Upper Laguna Madre, TX (ULM, n =  
96 13, Fig 1c), and Mississippi Sound, MS (MS, n = 30; Fig 1b) in the GoM. Of these 89 tissue  
97 samples, 63% were collected from male (n = 56) and 37% from female dolphins (n = 33).  
98 Samples from post-mortem animals were collected from five dolphins around Corpus Christi  
99 Bay, TX (adjacent to RB), and one dolphin in Baffin Bay, TX (near the connection to ULM). The  
100 limit of detection (LOD) for fentanyl, carisoprodol, and meprobamate were 0.07 ng/mL (ppb),  
101 0.30 ng/mL, and 2.00 ng/mL, respectively. The limit of quantification (LOQ) for fentanyl,  
102 carisoprodol, and meprobamate were 0.30 ng/mL, 0.50 ng/mL, and 10 ng/mL respectively.

103

### 104 *Pharmaceutical detection*

105 The identification of pharmaceutical compounds was confirmed based on the Orbitrap MS1 data  
106 of their adducts ( $[M+H]^+$  and  $[M+Na]^+$ ) with a mass error of less than 5 ppm, along with isotope  
107 pattern matching and a retention time deviation within  $\pm 0.4$  minutes of the corresponding  
108 standards. The pharmaceutical compounds were detected in the blubber of 30 dolphins (Table 1).  
109 For further details, please refer to the standards preparation and instrumental analysis sections.  
110 However, quantification was unattainable as no samples reached LOQ for any analyte. Fentanyl  
111 was found in 18 dolphins sampled by remote biopsy across the study sites and in all six post-  
112 mortem dolphins (27% of blubber samples; Table 1; Fig. 2; Supplemental Information Figures  
113 S1 and S2). Carisoprodol was detected in five dolphins (5.6% of blubber samples) while

<sup>4</sup> Lead Contact

114 meprobamate was detected in one dolphin (1.1% of blubber samples; Table 1; Supplemental  
115 Information Figures S1 and S2). One targeted pharmaceutical was detected in each of the  
116 samples where detections occurred.

117

### 118 *Sex and temporal patterns*

119 The distribution of pharmaceuticals between the sexes mirrored the demographics, with 63% of  
120 detections from males and 37% from females. RB had a high detection of pharmaceuticals  
121 relative to biopsy samples collected (RB: 49% biopsy samples, 62% pharmaceutical detections;  
122 ULM: 15% biopsy samples, 17% pharmaceutical detections; MS: 36% biopsy samples, 21%  
123 pharmaceuticals detected). Pharmaceuticals were found in 12 historic blubber samples from MS  
124 (2013) comprising 40% of total pharmaceutical detections.

125

### 126 **Discussion**

127 The data support that narcotic (opiate) analgesics and skeletal muscle relaxants can reach apex  
128 marine predators. The low (non-quantifiable) concentrations of opiate analgesics and muscle  
129 relaxants in dolphins in both Texas and Mississippi waters reinforce the need for large-scale  
130 assessments across trophic levels, water columns, and ecosystems globally; such widespread  
131 investigations will help ascertain the severity and source(s) of contamination<sup>25</sup>. We recommend  
132 initial efforts in areas with dense human populations and prominent aquaculture/fishing  
133 industries where humans may be most at risk. As 40% of all detected pharmaceuticals (n = 12)  
134 were found in the historical samples, pharmaceutical pollution may be a long-standing issue that

<sup>4</sup> Lead Contact



135 has been largely overlooked; assessment of historic water and tissue samples across marine taxa  
136 for pharmaceutical detection will provide insights into the duration of the issue.

137 Bioaccumulation of fentanyl through the consumption of contaminated prey cannot be  
138 discredited as the log Kow is 4.05<sup>38</sup>, bioaccumulation of carisoprodol is unlikely as the estimated  
139 log Kow is 2.36<sup>39</sup>, and meprobamate does not bioaccumulate as the log Kow is 0.07<sup>40</sup>. It is also  
140 possible that the dolphins were recently exposed to the pharmaceuticals. Monitoring  
141 concentrations of all three pharmaceuticals within the water column may help pinpoint sources  
142 of exposure. Fentanyl, carisoprodol, and meprobamate can cross the placental barrier with  
143 varying effects of toxicity<sup>41, 42</sup>. Offloading of fentanyl, carisoprodol, and meprobamate through  
144 lactational transfer occurs in some mammalian species<sup>43, 44</sup>, although this has not yet been  
145 explored in cetaceans.

146 Detection of narcotic (opiate) analgesics and skeletal muscle relaxants was overall higher  
147 in dolphins inhabiting RB and ULM compared to MS. In the years immediately following the  
148 2010 *Deepwater Horizon* oil spill (during which biopsy surveys were conducted), dolphins  
149 inhabiting Mississippi but not Texas experienced increased stranding rates<sup>45</sup>. However, dolphins  
150 inhabiting South Texas were deemed priority stocks by the National Oceanic and Atmospheric  
151 Administration due to High Cumulative Threat scores from compounded exposure to oil and gas  
152 pollution, vessel traffic, dredging and construction, and algal blooms<sup>46</sup>. Chronic exposure to  
153 multiple stressors can compromise the immune integrity of cetaceans, rendering them  
154 particularly susceptible to infection, reproductive failure, and mortality<sup>47</sup>. There is a need to  
155 proactively monitor contaminants of emerging concern (CECs) to inform mitigation efforts,  
156 particularly in regions with chronic and diverse stressors to marine biota.

<sup>4</sup> Lead Contact

157           Assessing the potential source(s) of exposure of the dolphins to narcotic (opiate)  
158 analgesics and skeletal muscle relaxants was beyond the scope of this study. However, our  
159 untargeted analysis was conducted on a dolphin found within one year of the largest liquid  
160 fentanyl drug bust in United States history in the adjacent county<sup>48</sup>, and fentanyl is stable in the  
161 ocean. The presence of human pharmaceuticals in free-swimming marine species is not usually  
162 assessed, and when tested, a targeted approach is often used due to the impracticality of testing  
163 all pharmaceutical classes<sup>20, 49</sup>. Initial non-targeted analyses of contaminants, especially in apex  
164 marine predators, allow for a broad assessment of the health of marine environments. Non-  
165 targeted studies may aid regulatory authorities in identifying and prioritizing which CECs to  
166 monitor and mitigate. However, non-targeted approaches should be followed by targeted  
167 analyses that verify CEC presence and quantify concentrations to enhance understandings of  
168 marine ecosystem health.

169           The detection of fentanyl in substantially more blubber samples than carisoprodol and  
170 meprobamate is expected as fentanyl readily distributes to fat. As carisoprodol and meprobamate  
171 have low bioconcentration factors in lipids, their detection in blubber (but not in blank samples)  
172 underscores the research potential for advanced mass spectrometry. It is unlikely (although  
173 potentially possible) that the detected analytes were in plasma within blubber as we did not use  
174 bloody biopsy samples. Concentrations below LD<sub>50</sub> suggest that acute toxicity is not of concern.  
175 However, chronic exposure and cumulative effects are unknown in marine mammals. Sublethal  
176 effects from chronic exposure to some pharmaceuticals can occur in fish, crustaceans, and  
177 arthropods<sup>50</sup>. Fentanyl was detected in all post-mortem dolphins in this study, and orphenadrine,  
178 pizotifen, or promethazine were detected in 70% of post-mortem dolphins in a different study<sup>27</sup>,  
179 possibly indicating some comorbidities. While toxicological studies on marine mammals are

<sup>4</sup> Lead Contact

180 limited due to conservation concerns and policies, *in vitro* and *in silico* studies may enable risk  
181 assessments of pharmaceuticals and other pollutants<sup>51</sup>, and assessments of synergistic effects.

182

### 183 **Resource Availability**

184 *Lead Contact:* Requests for further information and resources should be directed to and will be  
185 fulfilled by the lead contact, Dara Orbach ([dnorbach@gmail.com](mailto:dnorbach@gmail.com)).

186 *Materials Availability:* This study did not generate unique reagents.

187 *Data and Code Availability:* Data reported in this paper will be shared by the lead contact upon  
188 request. This paper does not report original code. Any additional information required to  
189 reanalyze the data reported in this paper is available from the lead contact upon request.

190

### 191 **Limitations of the study**

192 No sample reached LOQ for any analyte. Without quantification of pharmaceutical  
193 concentrations, the risk assessment to the dolphins and ecosystem is curtailed. However, the  
194 presence of carisoprodol and meprobamate in any blubber sample despite their low accumulation  
195 in lipids and brief half lives in mammals underscores the value of detection. Future research that  
196 quantifies pharmaceutical concentrations will be of value. A mass spectrometer capable of  
197 detecting concentration as low as femtomolar levels might enable the quantification of the low  
198 concentrations that occur in dolphins. Despite matches in retention time and m/z, we cannot  
199 definitively exclude the possibility of coeluting isobaric or isomeric metabolites. However, we  
200 are confident in our quality control and verification process as we had high mass accuracy

<sup>4</sup> Lead Contact

201 combined with retention time, used labeled standards, repeatedly tested blanks, and used MS2  
202 matching with our in-house database.

203 Remote biopsy sampling of blubber provides a way to assess thresholds of survival in  
204 marine mammals before possible comorbidities and cascading ecological effects occur. Blubber  
205 samples were used as a biological matrix because blubber can be collected from live, free-  
206 swimming dolphins by remote biopsy, which is non-lethal and substantially less invasive, costly,  
207 and logistically prohibitive compared to the live animal captures needed to obtain plasma and  
208 urine or post-mortem animals needed to obtain liver, kidney, and brain tissues. We did not have  
209 access to non-blubber tissue matrices from the post-mortem dolphins sampled. Sampling live-  
210 stranded animals that are subsequently euthanized may add insights of exposure levels if plasma,  
211 liver, kidney, or brain tissues can be assessed.

212 Because meprobamate is a metabolite of carisoprodol, it is unclear whether the dolphin in  
213 our study had metabolized carisoprodol or had been directly exposed to it. Only three  
214 pharmaceuticals were tested and were selected based on results of a non-targeted analysis. Each  
215 pharmaceutical assessed was present in at least one dolphin, but no dolphin had multiple  
216 pharmaceuticals detected. Testing additional pharmaceuticals could yield more CECs per  
217 dolphin. A statistical analysis was not possible due to the low number of blubber samples  
218 obtained and lower number of samples with pharmaceuticals detected. It was also not possible to  
219 control for different sampling years and unequal sampling efforts across study sites, which  
220 limited the scope of comparisons between locations.

221

## 222 **Acknowledgements**

<sup>4</sup> Lead Contact

223 We thank field data collection assistants: M. Applegate, K. Barry, E. Cano, A. Martinez, S.  
224 McBride, M. Foster, W. McGlaun, E. Mills, T. Ninke, J. Oster, L. Punjabi, J. Rich, E. Ronje, K.  
225 Simpson, J. Stevenot, A. Stiles, C. Thompson, J. Wicker, and A. Wilson. We thank M. Srinivasan  
226 and J. Litz from NOAA Southeast Fisheries Science Center, A. Moors from the National Institute  
227 for Standards and Technology, C. Ullmer from the Texas State Aquarium, and the Texas Marine  
228 Mammal Stranding Network. We thank the anonymous reviewers who provided helpful  
229 feedback. The scientific results and conclusions, as well as any views or opinions expressed  
230 herein, are those of the author(s) and do not necessarily reflect those of NOAA or the  
231 Department of Commerce. Funding was provided by Texas Parks and Wildlife Department (CA-  
232 0000891), TAMU-CC Center for Coastal Studies, Society of Integrative and Comparative  
233 Biology, and Frazier Family Foundation.

234

#### 235 **Author Contributions**

236 DNO, MAG, HA, and CW conceived the idea. CS, MAG, and DNO collected the data. AIO and  
237 MAG prepared the samples. AIO, MAG, HA, and JE analyzed the data. DNO and AIO wrote the  
238 manuscript with edits from MAG, JE, CS, CW, and HA.

239

#### 240 **Declaration of Interests**

241 The authors declare no competing interests.

242

#### 243 **Main Figure Titles and Legends**

<sup>4</sup> Lead Contact

244 **Fig. 1.** Study sites within the Gulf of Mexico with boating survey routes outlined in yellow. A)  
 245 Redfish Bay, TX; B) Mississippi Sound, MS; C) Upper Laguna Madre, TX. Images from Google  
 246 Earth. Remote biopsy samples were conducted in Redfish Bay from 2012-2014 and 2022, in  
 247 Upper Laguna Madre during 2022, and in Mississippi Sound during 2013. Post-mortem dolphin  
 248 tissue samples were collected from the Redfish Bay and Upper Laguna Madre vicinities in 2022-  
 249 2023.

251 **Fig. 2:** Mass spectrometer MS<sup>1</sup> chromatogram showing the overlaying of fentanyl peaks  
 252 [M+Na]<sup>+</sup> detected in 24 dolphin blubber samples with fentanyl present. Peaks represent the  
 253 intensity signal of the analyte when detected by the instrument.

## 255 Main Tables

256 **Table 1:** Number of dolphins with detected pharmaceuticals in blubber samples across three  
 257 study sites. The top numbers in each cell denote samples collected by remote biopsy of live (L)  
 258 dolphins and the bottom numbers denote samples collected from post-mortem (PM) dolphins.  
 259 The ratio of females to males are presented in brackets. Remote biopsy samples were collected in  
 260 Redfish Bay from 2012-2014 and 2022, in Upper Laguna Madre during 2022, and in Mississippi  
 261 Sound during 2013. Post-mortem dolphin tissue samples were collected from the Redfish Bay  
 262 and Upper Laguna Madre vicinities in 2022-2023.

Pharmaceutical	Redfish Bay, TX	Upper Laguna Madre, TX	Mississippi Sound, MS
L	41 (9:32)	12 (3:9)	30 (18:12)
PM	5 (3:2)	1 (0:1)	-

<sup>4</sup> Lead Contact

Fentanyl	L	12 (3:9)	4 (1:3)	2 (2:0)
	PM	5(3:2)	1 (0:1)	-
Carisoprodol	L	2 (0:2)	-	3 (2:1)
	PM	-	-	-
Meprobamate	L	1 (0:1)	-	-
	PM	-	-	-

263

264 **STAR Methods**265 **METHOD DETAILS**

266 **Study sites:** The Redfish Bay (RB) system, Texas, consists of dolphins inhabiting the inshore  
267 waters of Port Aransas, Texas, and extends to Aransas Bay, Texas. The survey area is  
268 approximately 260 km<sup>2</sup> with an average water depth of 4.3 m<sup>46</sup>. RB has one point of outflow to  
269 the Gulf of Mexico (GoM) near the town of Port Aransas. The RB system is connected to Corpus  
270 Christi Bay in the southwest<sup>46</sup>. The 2022 population abundance estimate of dolphins inhabiting  
271 RB is 1,104 dolphins (unpublished data). Peak abundance occurs in winter months and many  
272 dolphins are year-round residents<sup>52</sup>. Corpus Christi Bay connects to Laguna Madre (LM) through  
273 the narrow enclosed Intercoastal Waterway that spans 443 km in length and 3-6 km in width,  
274 with an average water depth of 1 m<sup>46</sup>. The Upper Laguna Madre (ULM) is the northern part of  
275 the LM system that extends from Corpus Christi Bay in the north to the land cut in the south,  
276 spanning 80 km. ULM connects to Baffin Bay in the west and there is no outflow of ULM to the  
277 GoM. The survey area of ULM is approximately 46 km<sup>2</sup>. Little research has been conducted on  
278 the dolphins inhabiting ULM<sup>46, 53</sup>. At least 408 different dolphins have been photo-documented  
279 between 2019-2022 (unpublished data). The Mississippi Sound (MS) is located off the

<sup>4</sup> Lead Contact

280 Mississippi coast, extending to Lake Borgne, Louisiana and Mobile Bay, Alabama, and bordered  
281 by the barrier islands of the Gulf Islands National Seashore to the south for a total area of  
282 approximately 4,792 km<sup>2</sup><sup>54, 55</sup>. MS varies in width from 7.2-22.5 km and has an average water  
283 depth of 3 m<sup>54</sup>. The surveyed area is approximately 643 km<sup>2</sup>. Dolphins inhabited MS exhibit  
284 seasonal spatial distributions, with peak densities during the summer<sup>55, 56, 57</sup>. The population  
285 abundance estimate is 1,265 dolphins in MS<sup>58</sup>.

286  
287  
288 **Remote Biopsy Sampling:** Research was conducted under NOAA NMFS permits 21938, 779-  
289 1633, and 14450, and Texas A&M University-Corpus Christi's Institutional Animal Care and  
290 Use Committee (IACUC) permit 2021-10-031. Blubber samples were obtained from distinct  
291 stocks of dolphins inhabiting Redfish Bay (RB) and Upper Laguna Madre (ULM), Texas, and  
292 Mississippi Sound (MS), Mississippi (Fig. 1). Remote biopsy surveys were conducted in RB  
293 from 2012-2014 and 2022, in ULM during 2022, and in MS during 2013. Historic samples from  
294 2012-2014 were used to explore the prevalence of pharmaceuticals over time. Research vessels  
295 included a 6.4 m Sea Fox with 200 HP motor, 7 m Boston Whaler Outrage with twin 150 HP  
296 motors, and 6 m rigid hull inflatable Inmar with 90 HP motor. Biopsy samples of dolphin blubber  
297 were collected using a crossbow (Barnett Panzer V, 68 kg draw weight) and custom-designed  
298 floating darts (Ceta-Dart) that rebound upon penetration of blubber<sup>59</sup>. A 7x25 mm or 10x25 mm  
299 stainless steel dart sampling tip held the tissue sample after penetration<sup>58</sup>. In between uses, tools  
300 including sampling tips were washed with antibacterial soap, rinsed, soaked in a 10% bleach  
301 solution for 10 minutes, rinsed again in deionized water, and autoclaved for 90 mins at 121 °C  
302 (15 psi). Groups with a neonate or calf < 1 year were avoided per federal permit regulations.

<sup>4</sup> Lead Contact



303 Initial GPS coordinates were recorded upon approaching dolphin groups. Samples were obtained  
304 from the flank of the dolphin, 3-4 inches below the dorsal fin and above the dolphin's midline.  
305 The sampling distance was typically 3-7 m from the target animal<sup>59</sup>.

306 Blubber samples were immediately retrieved from the darts and processed on ice using a  
307 cutting board covered with a sterile Teflon sheet. Sterilized scalpels and forceps were used to  
308 separate the blubber from skin. Samples were stored in vials sterilized by the National Institute  
309 of Standards and Technology in a liquid nitrogen vapor shipper until return to land and  
310 transferred to a -80°C freezer until processing. Metadata including environmental parameters,  
311 dolphin group composition, and biopsy data were recorded. Additional blubber samples were  
312 collected opportunistically from post-mortem dolphins (mostly fresh dead) that stranded in 2022-  
313 2023 in or near Redfish Bay and Upper Laguna Madre and were stored in -20°C freezers.

314

#### 315 ***Standards Preparation:***

316 All glassware was initially soaked in a 5% Tergazyme solution overnight, rinsed with tap water,  
317 washed with deionized (DI) water, soaked in 5% HCl for 12 hours, followed by further rinsing  
318 with DI water and Milli-Q ultrapure water. Glassware was subsequently oven-dried and  
319 combusted at 450°C for 12 hours. Immediately before use, glassware was rinsed with LC-MS  
320 Optima-grade acetonitrile (ACN). Procedure blanks (n = 3) underwent the same extraction  
321 processes but without the addition of the test blubber samples to ensure no contamination.

322 A combination of targeted and non-targeted approaches were employed<sup>60</sup> to identify  
323 which pharmaceuticals to assess (Methods S1). Both non-isotopically labeled pharmaceutical  
324 standards (fentanyl, carisoprodol, meprobamate, Sigma-Aldrich) and isotopically labeled

<sup>4</sup> Lead Contact

325 pharmaceutical standards (Fentanyl- $^{13}\text{C}_6$  with purity 99.5%, with 0.00%  $^{13}\text{C}_0$  vs  $^{13}\text{C}_6$ , 3.84%  $^{13}\text{C}_5$ ,  
326 0.09%  $^{13}\text{C}_4$  and 96.08%  $^{13}\text{C}_6$ ; Carisopropdol- $^{13}\text{C}_3$  with purity 99.5%, with 0.00% of  $^{13}\text{C}_0$  vs  $^{13}\text{C}_3$ ,  
327 2.58%,  $^{13}\text{C}_2$  97.43%; Meprobamate- $^{13}\text{C}_3$  with purity >98.7%, with 0.00%  $^{13}\text{C}_0$  vs  $^{13}\text{C}_3$ , 2.89%  
328  $^{13}\text{C}_2$ , 0.01%  $^{13}\text{C}_1$  and 97.10%  $^{13}\text{C}_3$ ) were used. The labeled standards were prepared in LCMS  
329 Optima-grade acetonitrile (ACN) at an initial concentration of 1 mg/mL (1,000 ppm). These  
330 standards were then combined to form a working solution with a final concentration of 1 ppm.  
331 The isotopically labeled pharmaceutical standards were used solely to validate the calibration  
332 curve and for spiking in the precision and recovery study. The isotopically labeled  
333 pharmaceutical standards were not spiked during sample analysis to prevent potential false  
334 positive detections from residual non-isotopically labeled standards. Successive serial dilutions  
335 were performed from the working solution to generate a calibration curve with concentrations  
336 ranging from 0.001 to 500 ng/mL. For the isotopically labeled standards, an additional dilution  
337 with a final concentration of 20 ng/mL was prepared for spiking test samples during the precision  
338 and recovery study (Methods S2).

339 The results of the precision and recovery study informed the decision to apply the same  
340 homogenization and pharmaceutical extraction method to all blubber samples, using a fixed mass  
341 of 150 mg blubber in ACN (Methods S2). Following extraction, all samples were reconstituted in  
342 150  $\mu\text{L}$  of ACN. Additionally, a blank sample of ACN was treated and analyzed multiple times  
343 during the sequence to ensure the accuracy of the result. Blubber homogenization and  
344 pharmaceutical extraction used combined techniques<sup>62, 63</sup>.

345

346 ***Instrumental Analysis:***

<sup>4</sup> Lead Contact

347 A Thermo Fisher Vanquish UHPLC system coupled with an ACQUITY UPLC BEH C18  
348 reverse-phase column (130 Å, 1.7 µm, 2.1 mm x 150 mm) and an Orbitrap Fusion Tribrid mass  
349 spectrometer were used for the analysis. The mass spectrometer was operated with the Orbitrap  
350 as a high-resolution mass analyzer, the quadrupole as a mass filter, and the ion trap for  
351 fragmentation spectra analysis. Pharmaceutical concentrations were quantified by running  
352 analytes extracted from blubber samples alongside non-labeled external standards. To avoid  
353 carryover between samples or from standards to samples in the LC-Orbitrap MS, the column is  
354 placed in 100% ACN for 3 min at the end of each analysis followed by a 7 min re-equilibration  
355 between runs to remove any residual carryover. We ran analysis blanks (ACN) at the beginning  
356 of each batch, after the calibration curve (twice), and after every 10 samples to check for  
357 potential carryover. Additionally, we analyzed procedure blanks (n=3) as samples, which serve  
358 as a control and consist of vials subjected to the same steps of the analytical procedure, including  
359 sample preparation, extraction, and analysis, but without the addition of blubber. In all blanks  
360 (both analysis and procedure), none of the targeted pharmaceutical compounds were detected.

361  
362 *Chromatographic Conditions:* The mobile phases consisted of Milli-Q (MQ) ultra-pure water  
363 with 1% formic acid (A) and acetonitrile (ACN) with 1% formic acid (B). The chromatographic  
364 separation was performed at a flow rate of 0.200 mL/min with the total run lasting 31 min with a  
365 7 min re-equilibration and the following gradient: 0 - 2 min hold at 5% B, ramp to 65% B for 18  
366 min, ramp to 100% B for 1 min, and hold at 100% B for 3 min. Samples were injected at a  
367 volume of 5 µL.

368

369 *Mass Spectrometry Conditions: UHPLC element was ionized using heated electrospray*  
370 *ionization (H-ESI) at 3,500 volts in positive ion mode. The ion transfer tube temperature was set*  
371 *to 300°C and the vaporization temperature to 225°C. Gas flow rates were set at 35 for sheath gas,*  
372 *7 for auxiliary gas, and 0 for sweep gas. The Orbitrap operated at 60,000 FWHM resolution (at*  
373 *200 m/z), with a mass range of 85–700 m/z and an RF lens setting of 40%.*

374 For each Orbitrap acquisition cycle, we prioritized acquiring MS/MS fragmentation  
375 spectra of three pharmaceuticals using the ion trap, focusing on their specific retention times.  
376 Secondary priority was assigned to two additional MS/MS scans, performed using a data-  
377 dependent acquisition (DDA) approach with a quadrupole isolation window of 0.7 m/z. The first  
378 MS/MS scan employed collision-induced dissociation (CID) with an automatic gain control  
379 (AGC) target of  $3.0 \times 10^4$  and a maximum injection time of 50 ms. The second MS/MS scan  
380 used higher-energy collisional dissociation (HCD), with collision energy optimized through real-  
381 time assisted optimization at 15, 30, and 45 eV, and an AGC target of  $1.0 \times 10^4$ . By incorporating  
382 reference standards to confirm retention times and ensuring high mass accuracy, we confidently  
383 assign our identifications to Level 1<sup>61</sup>.

384

## 385 **QUANTIFICATION AND STATISTICAL ANALYSIS**

386 *Data Analysis and Quantification: TraceFinder 5.1 (Thermo Scientific) was used to determine*  
387 *analyte peak areas and retention times for the [M+H]<sup>+</sup> and [M+Na]<sup>+</sup> adducts. Concentrations*  
388 *were calculated by applying the peak areas to the analytes' standard calibration curves. Percent*  
389 *recovery and precision (standard deviation) were determined for each analyte.*

390

<sup>4</sup> Lead Contact

391 *Limit of Detection (LOD) and Limit of Quantification (LOQ)*: The LOD was established by  
392 performing 9 replicate injections, ensuring a signal-to-noise (S/N) ratio > 3, a mass error < 5  
393 ppm, isotope patterns, and a retention time deviation within  $\pm 0.4$  min of the corresponding  
394 standard. Multiple adducts ( $[M+H]^+$  and  $[M+Na]^+$ ) were evaluated, with the lowest LOD value  
395 selected.

396 For LOQ, a S/N ratio > 10 was required, along with MS/MS fragmentation spectra  
397 collected in the ion trap. LOQ determination also required a mass error < 5 ppm and retention  
398 time detection within  $\pm 0.4$  min of the pharmaceutical standard and a minimum of three matching  
399 fragments were required for confirmation.

400

#### 401 **Supplemental Information**

402 Methods S1, Methods S2, Tables S1-S2, Figures S1-S2.

403

#### 404 **References**

- 405 1. Blaser, M. J., Melby, M. K., Lock, M., and Nichter, M. Accounting for variation in and  
406 overuse of antibiotics among humans. *BioEssays* **43(2)**, 2000163 (2021).  
407 <https://doi.org/10.1002/bies.202000163>
- 408 2. Jones, C. M., Mack, K. A., and Paulozzi, L. J. Pharmaceutical overdose deaths, United States,  
409 2010. *JAMA* **309(7)**, 657–659 (2013). <https://doi.org/10.1001/jama.2013.272>
- 410 3. Woodward, K. N. Adverse effects of veterinary pharmaceutical products in animals.  
411 In Woodward, K.N. (Ed.) *Veterinary pharmacovigilance: Adverse reaction to veterinary*  
412 *medicinal products* (pp. 393–421). Chichester, United Kingdom: Wiley Blackwell.  
413 (2009). <https://doi.org/10.1002/9781444322958>

- 414 4. Chavoshani, A., Hashemi, M., Amin, M. M., and Ameta, S. C. Pharmaceuticals as emerging  
415 micropollutants in aquatic environments. In Munro, L. (Ed.) *Micropollutants and*  
416 *Challenges: Emerging in the Aquatic Environments and Treatment Processes* pp. 35–90.  
417 Amsterdam, Netherlands: Elsevier (2020).
- 418 5. aus der Beek, T., Weber, F.-A., Bergmann, A., Hickmann, S., Ebert, I., Hein, A., and Küster, A.  
419 Pharmaceuticals in the environment-global occurrences and perspectives. *Environ. Toxic.*  
420 *Chem.* **35(4)**, 823–835 (2016). <https://doi.org/10.1002/etc.3339>
- 421 6. Zandaryaa, S., and Frank-Kamenetsky, D. A source-to-sea approach to emerging pollutants in  
422 freshwater and oceans: Pharmaceuticals in the Baltic Sea region. In Weinberg, J., Qinhuu,  
423 F., Zandaryaa, S., Leslie, G., and Nickum, J. E. *Source-to-Sea Management* pp. 60-75.  
424 London, U.K.: Routledge (2021).
- 425 7. Wilkinson, J. L. *et al.* Pharmaceutical pollution of the world's rivers. *Proc. Natl. Acad. Sci.*  
426 **119(8)**, 1–10 (2022). <https://doi.org/10.1073/pnas.2113947119>
- 427 8. Gaw, S., Thomas, K. V., and Hutchinson, T. H. Sources, impacts and trends of pharmaceuticals  
428 in the marine and coastal environment. *Phil. Trans. R. Soc. B.* **369(1656)**, 20130572  
429 (2014). <https://doi.org/10.1098/rstb.2013.0572>
- 430 9. Kleywegt, S., Payne, M., Ng, F., and Fletcher, T. Environmental loadings of active  
431 pharmaceutical ingredients from manufacturing facilities in Canada. *Sci. Tot. Environ.* **46**,  
432 257–264 (2019). <https://doi.org/10.1016/j.scitotenv.2018.07.240>
- 433 10. Khasawneh, O.F.S., and Palaniandy, P. Occurrence and removal of pharmaceuticals in  
434 wastewater treatment plants. *Proc. Safe. Environ. Protect.* **150**, 532-556M (2021).  
435 <https://doi.org/10.1016/j.psep.2021.04.045>

- 436 11. Ulvi, A., Aydin, S., and Aydin, M.E. Fate of selected pharmaceuticals in hospital and  
437 municipal wastewater effluent: Occurrence, removal, and environmental risk assessment.  
438 *Environ. Sci. Pollut. Res.* **29**, 75609–75625 (2022). [https://doi.org/10.1007/s11356-022-](https://doi.org/10.1007/s11356-022-21131-y)  
439 [21131-y](https://doi.org/10.1007/s11356-022-21131-y)
- 440 12. Kümmerer, K. Pharmaceuticals in the environment. *Ann. Rev. Environ. Resour.* **35(1)**, 57–75  
441 (2010). <https://doi.org/10.1146/annurev-environ-052809-161223>
- 442 13. Le, T. X., Munekage, Y., and Kato, S.-I. Antibiotic resistance in bacteria from shrimp farming  
443 in mangrove areas. *Sci. Tot. Environ.* **349**, 95–105 (2005).  
444 <https://doi.org/10.1016/j.scitotenv.2005.01.006>
- 445 14. Fabri, E., and Franzellitti, S. HuEman pharmaceuticals in the marine environment: Focus on  
446 exposure and biological effects in animal species. *Environ. Toxicol. Chem.* **2016(35)**,  
447 799–812 (2016). <https://doi.org/10.1002/etc.3131>
- 448 15. Mezzelani, M., Gorbi, S., and Regoli, F. Pharmaceuticals in the aquatic environments:  
449 Evidence of emerged threat and future challenges for marine organisms. *Mar. Environ.*  
450 *Res.* **140**, 41-60 (2018). <https://doi.org/10.1016/j.marenvres.2018.05.001>
- 451 16. Ruan, Y., Lin, H., Zhang, X., Wu, R., Zhang, K., Leung, K.M., Lam, J.C., and Lam, P.K.  
452 Enantiomer-specific bioaccumulation and distribution of chiral pharmaceuticals in a  
453 subtropical marine food web. *J. Haz. Mat.* **394**, 122589 (2020).  
454 <https://doi.org/10.1016/j.jhazmat.2020.122589>
- 455 17. Ruhí, A., Acuña, V., Barceló, D., Huerta, B., Mor, J.R., Rodríguez-Mozaz, S., and Sabater, S.  
456 Bioaccumulation and trophic magnification of pharmaceuticals and endocrine disruptors  
457 in a Mediterranean river food web. *Sci. Tot. Environ.* **540**, 250–259 (2016).  
458 <https://doi.org/10.1016/j.scitotenv.2015.06.009>

- 459 18. Xie, Z., Lu, G., Yan, Z., Liu, J., Wang, P., and Wang, Y. Bioaccumulation and trophic transfer  
460 of pharmaceuticals in food webs from a large freshwater lake. *Environ. Poll.* **222**, 356–  
461 366 (2017). <https://doi.org/10.1016/j.envpol.2016.12.026>
- 462 19. Brodin, T., Piovano, S., Fick, J., Klaminder, J., Heynen, M. and Jonsson, M. Ecological  
463 effects of pharmaceuticals in aquatic systems—impacts through behavioural alterations.  
464 *Phil. Trans. R. Soc. B.* **369(1656)**, 20130580 (2014).  
465 <https://doi.org/10.1098/rstb.2013.0580>
- 466 20. Schmitz, M., Beghin, M., Mandiki, S. N., Nott, K., Gillet, M., Ronkart, S., Robert, C.,  
467 Baekelandt, S., and Kestemont, P. Environmentally-relevant mixture of pharmaceutical  
468 drugs stimulates sex-steroid hormone production and modulates the expression of  
469 candidate genes in the ovary of juvenile female rainbow trout. *Aqua. Toxic.* **205**, 89-99  
470 (2018). <https://doi.org/10.1016/j.aquatox.2018.10.006>
- 471 21. Biswas, C., Maity, S., Adhikari, M., Chatterjee, A., Guchhait, R., and Pramanick, K.  
472 Pharmaceuticals in the aquatic environment and their endocrine disruptive effects in fish.  
473 *Proc. Zool. Soc.* **74(4)**, 507–522 (2021). <https://doi.org/10.1007/s12595-021-00402-5>
- 474 22. Collier, R. Swallowing the pharmaceutical waters. *Can. Med. Assoc. J.* **184(2)**, 163–164.  
475 (2012). <https://doi.org/10.1503/cmaj.109-4086>
- 476 23. Martínez-Morcillo, S., Rodríguez-Gil, J.L., Fernández-Rubio, J., Rodríguez-Mozaz, S.,  
477 Míguez-Santiyán, M.P., Valdes, M.E., Barceló, D., and Valcárcel, Y. Presence of  
478 pharmaceutical compounds, levels of biochemical biomarkers in seafood tissues and risk  
479 assessment for human health: Results from a case study in North-Western Spain. *Intl. J.*  
480 *Hyg. Environ. Health* **223(1)**, 10–21 (2020). <https://doi.org/10.1016/j.ijheh.2019.10.011>



- 481 24. Ture, M., Fentie, T., and Regassa, B. Veterinary drug residue: The risk, public health  
482 significance and its management. *Vet. Sci. J.* **13(2)**, 1–11 (2019).
- 483 25. Gkotsis, G., et al. Assessment of contaminants of emerging concern in European apex  
484 predators and their prey by LC-QToF MS wide-scope target analysis. *Environ. Intl.* **170**,  
485 107623 (2022). <https://doi.org/10.1016/j.envint.2022.107623>
- 486 26. Gelsleichter, J., and Szabo, N. J. Uptake of human pharmaceuticals in bull sharks  
487 (*Carcharhinus leucas*) inhabiting a wastewater-impacted river. *Sci. Tot. Environ.* **456**,  
488 196–201 (2013). <https://doi.org/10.1016/j.scitotenv.2013.03.078>
- 489 27. Alzola-Andres, M., Cervený, D., Domingo-Echaburu, S., Lekube, X., Ruiz-Sancho, L.,  
490 Brodin, T., Orive, G., and Lertxundi, U. Pharmaceutical residues in stranded dolphins in  
491 the Bay of Biscay. *Sci. Tot. Environ.* **912**, 168570 (2024).  
492 <https://doi.org/10.1016/j.scitotenv.2023.168570>
- 493 28. Ross, A. R., Liao, X., and Brown, T. M. Simultaneous determination of steroid hormones and  
494 pharmaceuticals in killer whale (*Orcinus orca*) faecal samples by liquid chromatography  
495 tandem mass spectrometry. *Conserv. Physiol.* **11(1)**, coad081 (2023).  
496 <https://doi.org/10.1093/conphys/coad081>
- 497 29. Aguilar, A., Borrell, A., and Pastor, T. Biological factors affecting variability of persistent  
498 pollutant levels in cetaceans. *J. Cetacean Res. Manage.* **S1**, 83–116 (1999).  
499 <https://doi.org/10.47536/jcrm.v1i1.264>
- 500 30. Kucklick, J., Boggs, A., Huncik, K., Moors, A., Davis, E., Ylitalo, G., McConnell, M.,  
501 Makris, C., and Wells, R.S. Temporal trends of persistent organic pollutants in Sarasota  
502 Bay common bottlenose dolphins (*Tursiops truncatus*). *Front. Mar. Sci.* **9**, 1–14 (2022).  
503 <https://doi.org/10.3389/fmars.2022.763918>


- 504 31. Baptista, G., Kehrig, H.A., Di Benedetto, A.P.M., Hauser-Davis, R.A., Almeida, M.G.,  
505 Rezende, C.E., Siciliano, S., de Moura, J.F., and Moreira, I. Mercury, selenium and stable  
506 isotopes in four small cetaceans from the southeastern Brazilian coast: Influence of  
507 feeding strategy. *Environ. Pollut.* **218**, 1298–1307 (2016).  
508 [doi.org/10.1016/j.envpol.2016.08.088](https://doi.org/10.1016/j.envpol.2016.08.088)
- 509 32. Drug Enforcement Administration. *Drug fact sheet: Fentanyl* [Fact sheet] (2022)  
510 [www.dea.gov/sites/default/files/2023-06/Fentanyl%202022%20Drug%20Fact%20Sheet-](https://www.dea.gov/sites/default/files/2023-06/Fentanyl%202022%20Drug%20Fact%20Sheet-update.pdf)  
511 [update.pdf](https://www.dea.gov/sites/default/files/2023-06/Fentanyl%202022%20Drug%20Fact%20Sheet-update.pdf)
- 512 33. Van Dolah, F. M., Neely, M. G., McGeorge, L. E., Balmer, B. C., Ylitalo, G. M., Zolman, E.  
513 S., Speakman, T., Sinclair, C., Kellar, N. M., Rosel, P. E., and Mullin, K.D. Seasonal  
514 variation in the skin transcriptome of common bottlenose dolphins (*Tursiops truncatus*)  
515 from the northern Gulf of Mexico. *PLoS One*, **10(6)**, e0130934 (2015).  
516 <https://doi.org/10.1371/journal.pone.o130934>
- 517 34. Ramos-Matos C. F, Bistas K. G, Lopez-Ojeda W. Fentanyl [Updated 2023 May 29]. In:  
518 *StatPearls* [Internet]. Treasure Island (FL): StatPearls Publishing (2024). Available from:  
519 <https://www.ncbi.nlm.nih.gov/books/NBK459275/>
- 520 35. Berger, F. M., Kletzklin, M., Ludwig, B. J., and Margolin, S. The history, chemistry, and  
521 pharmacology of carisoprodol. *Ann. NY Acad. Sci.* **86(1)**, 90–107 (1960).  
522 <https://doi.org/10.1111/j.1749-6632.1960.tb42792.x>
- 523 36. LiverTox: Clinical and research information on drug-induced liver injury. *National Institute*  
524 *of Diabetes and Digestive and Kidney Diseases*, Bethesda (MD), (2019). PMID:  
525 31643176.

- 526 37. Conermann T, and Christian D. Carisoprodol [Updated 2024 May 2]. In: *StatPearls*  
527 [Internet]. Treasure Island (FL): StatPearls Publishing (2024). Available from:  
528 <https://www.ncbi.nlm.nih.gov/books/NBK553077/>
- 529 38. Sangster, J. *LOGKOW Databank*. Sangster Res. Lab., Montreal Quebec, Canada (1993).
- 530 39. Meylan, W. M., and Howard, P. H. Atom/fragment contribution method for estimating  
531 octanol–water partition coefficients. *J. Pharm. Sci.* **84(1)**, 83–92 (1995).  
532 <https://doi.org/10.1002/jps.2600840120>
- 533 40. Hansch, C., Leo, A. and Hoekman, D. *Exploring QSAR: hydrophobic, electronic, and steric*  
534 *constants* (Vol. 2). Washington, DC: American Chemical Society (1995).
- 535 41. Cooper, J., Jauniaux, E., Gulbis, B., Quick, D., and Bromley, L. Placental transfer of fentanyl  
536 in early human pregnancy and its detection in fetal brain. *Brit. J. Anaesth.* **82(6)**, 929–931  
537 (1999). <https://doi.org/10.1093/bja/82.6.929>
- 538 42. Weiner, C. P. *Drugs for Pregnant and Lactating Women E-Book*. Elsevier Health Sciences,  
539 (2018).
- 540 43. Cohen, R. S. Fentanyl transdermal analgesia during pregnancy and lactation. *J. Hum. Lact.*  
541 **25(3)**, 359–361 (2009). <https://doi.org/10.1177/089033440933334>
- 542 44. Nordeng, H., Zahlsen, K., and Spigset, O. Transfer of carisoprodol to breast milk. *Therap.*  
543 *Drug Monit.* **23(3)**, 298–300 (2001).
- 544 45. Venn-Watson, S., Garrison, L., Litz, J., Fougères, E., Mase, B., et al. Demographic clusters  
545 identified within the northern Gulf of Mexico common bottlenose dolphin (*Tursiops*  
546 *truncatus*) unusual mortality event: January 2010–June 2013. *PLoS One* **10(2)**, e0117248  
547 (2015). <https://doi.org/10.1371/journal.pone.0117248>

- 548 46. Phillips N. M., and Rosel P. E. A method for prioritizing research on common bottlenose  
549 dolphin stocks through evaluating threats and data availability: Development and  
550 application to bay, sound and estuary stocks in Texas. *NOAA Tech. Memo. NMFS-*  
551 **SEFSC-665** (2014). <http://doi.org/10.7289/V5F769H8>
- 552 47. Fossi, M. C., and Panti, C. (Eds.). *Marine Mammal Ecotoxicology: Impacts of Multiple*  
553 *Stressors on Population Health*. London, U.K.: Academic Press (2018).
- 554 48. Wilson, W., and Adami, L. *Nueces County traffic stop turns into largest liquid fentanyl drug*  
555 *bust in US history*. KIII News. (2022, December 5).  
556 [www.kiiitv.com/article/news/local/nueces-county-traffic-stop-turns-into-largest-liquid-](http://www.kiiitv.com/article/news/local/nueces-county-traffic-stop-turns-into-largest-liquid-fentanyl-drug-bust-in-us-history/503-80e7b86d-0f82-420f-bb0b-f1c8d244aebc)  
557 [fentanyl-drug-bust-in-us-history/503-80e7b86d-0f82-420f-bb0b-f1c8d244aebc](http://www.kiiitv.com/article/news/local/nueces-county-traffic-stop-turns-into-largest-liquid-fentanyl-drug-bust-in-us-history/503-80e7b86d-0f82-420f-bb0b-f1c8d244aebc)
- 558 49. Tanoue, R., Margiotta-Casaluci, L., Huerta, B., Runnalls, T. J., Nomiyama, K., Kunisue, T.,  
559 Tanabe, S., and Sumpter, J. P. Uptake and metabolism of human pharmaceuticals by fish:  
560 A case study with the opioid analgesic tramadol. *Environ. Sci. Tech.* **51(21)**, 12825–  
561 12835 (2017). <https://doi.org/10.1021/acs.est.7b03441>
- 562 50. Srain, H. S., Beazley, K. F., and Walker, T. R. Pharmaceuticals and personal care products  
563 and their sublethal and lethal effects in aquatic organisms. *Environ. Rev.* **29(2)**, 142–181  
564 (2021). <https://doi.org/10.1139/er-2020-0054>
- 565 51. Weijs, L., and Zaccaroni, A. Toxicology of marine mammals: New developments and  
566 opportunities. *Arch. Environ. Contam. Toxicol.* **70(1)**, 1–8 (2016).  
567 <https://doi.org/10.1007/s00244-015-0233-9>
- 568 52. Shane S.H. Occurrence, movements, and distribution of bottlenose dolphin, *Tursiops*  
569 *truncatus*, in southern Texas. *Fish. Bull.* **78(3)**, 593–601 (1980)

- 570 53. Leatherwood S., and Reeves R. R. Abundance of bottlenose dolphins in Corpus Christi Bay  
571 and coastal southern Texas. *Contrib. Mar. Sci.* **26**, 179–199 (1983).  
572 <http://hdl.handle.net/1969.3/21288>
- 573 54. Handley L. R., Spear K. A., Leggett A., and Thatcher C.A. *Mississippi Sound*. United States  
574 Geological Survey, 2012 (2012). [www.usgs.gov/publications/mississippi-sound#connect](http://www.usgs.gov/publications/mississippi-sound#connect)
- 575 55. Miller L. J., Mackey A. D., Solangi M., and Kuczaj S. A. Population abundance and habitat  
576 utilization of bottlenose dolphins in the Mississippi Sound. *Aqua. Conserv.* **23(1)**, 145–  
577 151 (2013). <https://doi.org/10.1002/aqc.2278>
- 578 56. Pitchford, J. L., Howard, V. A., Shelley, J. K., Serafin, B. J., Coleman, A. T., and Solangi, M.  
579 Predictive spatial modelling of seasonal bottlenose dolphin (*Tursiops truncatus*)  
580 distributions in the Mississippi Sound. *Aqua. Conserv.* **26(2)**, 289–306 (2015).  
581 <https://doi.org/10.1002/aqc.2547>
- 582 57. Vollmer N.L., *et al.* Assessing common bottlenose dolphin (*Tursiops truncatus*) population  
583 structure in Mississippi Sound and coastal waters of the North Central Gulf of Mexico.  
584 *Aqua. Conserv.* **31(10)**, 2951–2966 (2021). <https://doi.org/10.1002/aqc.3668>
- 585 58. Garrison L. P., Ortega-Ortiz, J., and Rappucci, G. Abundance of coastal and continental shelf  
586 stocks of common bottlenose and Atlantic spotted dolphins in the Northern Gulf of  
587 Mexico: 2017-18. *NOAA Tech. Memo. NMFS-SEFSC PRD-2021-01* (2021).  
588 <https://doi.org/10.25923/vk95-t881>
- 589 59. Sinclair, C., Sinclair, J., Zolman, E. S., Martinez, A., Riishøjgaard, L. P., and Barry, K. P.  
590 Remote biopsy field sampling procedures for cetaceans used during the Natural Resource  
591 Damage Assessment of the MSC252 Deepwater Horizon oil spill. *NOAA Tech. Memo.*  
592 **NMFS-SEFSC-670** (2015). <http://doi.org/10.7289/V5CC0XN0>

- 593 60. Amer, B., Deshpande, R. R., and Bird, S. S. Simultaneous quantitation and discovery  
594 (SQUAD) analysis: Combining the best of targeted and untargeted mass spectrometry-  
595 based metabolomics. *Metabolites* **13**(5), 648 (2023).  
596 <https://doi.org/10.3390/metabo13050648>
- 597 61. Schymanski, E. L., Jeon, J., Gulde, R., Fenner, K., Ruff, M., Singer, H. P., and Hollender, J.  
598 Identifying small molecules via high resolution mass spectrometry: Communicating  
599 confidence. *Environ. Sci. Technol.* **48**(4), 2097–2098 (2014).  
600 <https://doi.org/10.1021/es5002105>
- 601 62. Boggs, A. S., Schock, T. B., Schwacke, L. H., Galligan, T. M., Morey, J. S., McFee, W. E.,  
602 and Kucklick, J.R. Rapid and reliable steroid hormone profiling in *Tursiops truncatus*  
603 blubber using liquid chromatography tandem mass spectrometry (LC-MS/MS). *Anal.*  
604 *Bioanal. Chem.* **409**(21), 5019–5029 (2017). <https://doi.org/10.1007/s00216-017-0446-z>
- 605 63. Wittmaack, C. *et al.* Small blubber samples (50 mg) sufficient for analyses of 10 stress and  
606 reproductive steroid hormones in gray and fin whales via liquid chromatography mass  
607 spectrometry. *Front. Mar. Sci.* **8**, 2080 (2022). <https://doi.org/10.3389/fmars.2021.808764>







## Highlights

- Bottlenose dolphins are bioindicator species of ecosystem health
- Pharmaceuticals found in the blubber of 30 dolphins (24 live) in the Gulf of Mexico
- Detected pharmaceuticals included opioids, muscle relaxants, and sedatives
- Pharmaceuticals in the marine ecosystem appear to be a long-standing issue

Journal Pre-proof

**Key resources table**

REAGENT or RESOURCE	SOURCE	IDENTIFIER
Biological samples		
N/A- wild animals	N/A- wild animals	N/A- wild animals

Journal Pre-proof